|
|
|
Volumn 22, Issue 139, 2013, Pages 149-
|
|
Belimumab. No tangible efficacy but a risk of immunosuppression.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BELIMUMAB;
IMMUNOSUPPRESSIVE AGENT;
MONOCLONAL ANTIBODY;
ARTICLE;
DOUBLE BLIND PROCEDURE;
DRUG EFFECT;
HUMAN;
IMMUNOLOGICAL TOLERANCE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SYSTEMIC LUPUS ERYTHEMATOSUS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
DOUBLE-BLIND METHOD;
HUMANS;
IMMUNE TOLERANCE;
IMMUNOSUPPRESSIVE AGENTS;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
|
|
EID: 84881502359
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|